During the last session, Zosano Pharma Corporation (NASDAQ:ZSAN)’s traded shares were 3.35 million, with the beta value of the company hitting 3.76. At the end of the trading day, the stock’s price was $0.94, reflecting an intraday gain of 2.40% or $0.02. The 52-week high for the ZSAN share is $3.06, that puts it down -225.53 from that peak though still a striking 64.89% gain since the share price plummeted to a 52-week low of $0.33. The company’s market capitalization is $98.69M, and the average intraday trading volume over the past 10 days was 3.11 million shares, and the average trade volume was 2.84 million shares over the past three months.
Zosano Pharma Corporation (ZSAN) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.70. ZSAN has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.08.
Zosano Pharma Corporation (NASDAQ:ZSAN) trade information
Zosano Pharma Corporation (ZSAN) registered a 2.40% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 2.40% in intraday trading to $0.94 this Wednesday, 06/09/21, hitting a weekly high. The stock’s 5-day price performance is 17.10%, and it has moved by 17.74% in 30 days. Based on these gigs, the overall price performance for the year is -4.89%. The short interest in Zosano Pharma Corporation (NASDAQ:ZSAN) is 6.97 million shares and it means that shorts have 3.55 day(s) to cover.
The consensus price target of analysts on Wall Street is $2.17, which implies an increase of 56.68% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $2.00 and $2.50 respectively. As a result, ZSAN is trading at a discount of -165.96% off the target high and -112.77% off the low.
Zosano Pharma Corporation (ZSAN) estimates and forecasts
Statistics show that Zosano Pharma Corporation has outperformed its competitors in share price, compared to the industry in which it operates. Zosano Pharma Corporation (ZSAN) shares have gone up 57.01% during the last six months, with a year-to-date growth rate more than the industry average at 34.69% against 9.00. Yet analysts are ramping up their growth forecast for the fiscal year 2021. Revenue is predicted to grow 42.90% this quarter and then jump 36.40% in the quarter after that. In the rating firms’ projections, revenue will increase 645.50% compared to the previous financial year.
Revenue for the current quarter is expected to be $270k as predicted by 3 analyst(s). Meanwhile, a consensus of 3 analyst(s) estimates revenue growth to $1.03 million by the end of Sep 2021.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 60.30%. While earnings are projected to return 78.60% in 2021.
Zosano Pharma Corporation is due to release its next quarterly earnings in July. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Zosano Pharma Corporation (NASDAQ:ZSAN)’s Major holders
Zosano Pharma Corporation insiders own 0.32% of total outstanding shares while institutional holders control 13.34%, with the float percentage being 13.39%. Vanguard Group, Inc. (The) is the largest shareholder of the company, while 42 institutions own stock in it. As of Mar 30, 2021, the company held over 3.83 million shares (or 3.59% of all shares), a total value of $4.75 million in shares.
The next largest institutional holding, with 2.72 million shares, is of Aisling Capital Management LP’s that is approximately 2.55% of outstanding shares. At the market price on Mar 30, 2021, these shares were valued at $3.37 million.
Also, the Mutual Funds coming in first place with the largest holdings of Zosano Pharma Corporation (ZSAN) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. Data provided on Mar 30, 2021 indicates that Vanguard Total Stock Market Index Fund owns about 2.57 million shares. This amounts to just over 2.40 percent of the company’s overall shares, with a $3.18 million market value. The same data shows that the other fund manager holds slightly less at 1.09 million, or about 1.02% of the stock, which is worth about $1.35 million.